Intelligence Feed event · Macro · 2026-10-07

    Oculis to Present Licaminlimab at Eyecelerator Ahead of PREDICT-1 Readout

    Question

    Oculis to Present Licaminlimab at Eyecelerator Ahead of PREDICT-1 Readout

    Direct answer

    Oculis announced that its Chief Executive Officer, Riad Sherif, will present Licaminlimab at the Eyecelerator @ AAO 2026 meeting on October 8. Licaminlimab is a topical biologic targeting TNFR1 for dry eye disease. The company reaffirmed that the PREDICT-1 registrational trial remains on schedule for topline readout by the end of 2026, establishing a concrete binary catalyst window for ophthalmic biotech investors.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-07
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Oculis to Present Licaminlimab at Eyecelerator Ahead of PREDICT-1 Readout”, revision 1, evidence through 2026-10-07. https://marketontology.com/market-events/2026-10-07/oculis-to-present-licaminlimab-at-eyecelerator-ahead-of-predict-1-readout-915da5

    MACRO
    Oculis to Present Licaminlimab at Eyecelerator Ahead of PREDICT-1 Readout
    Oculis announced that its Chief Executive Officer, Riad Sherif, will present Licaminlimab at the Eyecelerator @ AAO 2026 meeting on October 8. Licaminlimab is a topical biologic targeting TNFR1 for dry eye disease. The company reaffirmed that the PREDICT-1 registrational trial remains on schedule for topline readout by the end of 2026, establishing a concrete binary catalyst window for ophthalmic biotech investors.
    OCS
    Impact
    56
    OCT 7
    SIG
    85%
    OCS
    Oculis to Present Licaminlimab at Eyecelerator Ahead of PREDICT-1 Readout
    Oculis announced that its Chief Executive Officer, Riad Sherif, will present Licaminlimab at the Eyecelerator @ AAO 2026 meeting on October 8. Licaminlimab is a topical biologic targeting TNFR1 for dry eye disease. The company reaffirmed that the PREDICT-1 registrational trial remains on schedule for topline readout by the end of 2026, establishing a concrete binary catalyst window for ophthalmic biotech investors.
    → Confirmation of year-end registrational phase-3 data milestones concentrates binary clinical trial option implied volatility into OCS equity pricing.
    Impact
    Oculis announced that its Chief Executive Officer, Riad Sherif, will present Licaminlimab at the Eyecelerator @ AAO 2026 meeting on October 8. Licaminlimab is a topical biologic targeting TNFR1 for dry eye disease. The company reaffirmed that the PREDICT-1 registrational trial remains on schedule for topline readout by the end of 2026, establishing a concrete binary catalyst window for ophthalmic biotech investors.
    Affected
    OCS
    Transmission
    Confirmation of year-end registrational phase-3 data milestones concentrates binary clinical trial option implied volatility into OCS equity pricing.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    OCSclinical pipeline milestone clarity and upcoming catalyst positioningUp1-3mPresentation at AAO 2026 and confirmation of year-end PREDICT-1 topline readout

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month